Breast Cancer Articles

Bypassing Endocrine Resistance in Advanced HR+ Breast Cancer
Christopher R. Chitambar, MD, FACP, discusses the research that led to the development of CDK4/6 inhibitors in metastatic HR-positive, HER2-negative breast cancer and the significance of the PI3K inhibitor alpelisib.
Talazoparib Approved in Europe for BRCA-Mutant Breast Cancer
The European Commission has approved single-agent talazoparib for the treatment of adult patients with germline BRCA1/2-mutant, HER2-negative locally advanced or metastatic breast cancer.
O'Regan Assesses Treatment Courses and Durations in Early-Stage HR+ Breast Cancer
Ruth O'Regan, MD, discusses current approaches to treatment escalation and de-escalation, as well as the use of retrospective molecular profiling, which may help address some unanswered questions in the field.
Neratinib Combo Improves PFS in HER2+ Breast Cancer
Neratinib combined with capecitabine reduced the risk of disease progression or death by 24% compared with lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer who received at least 2 prior lines of HER2-targeted therapy.
Capivasertib Combined With Fulvestrant Improves PFS in ER+ Breast Cancer
Adding the Akt inhibitor capivasertib to fulvestrant led to a more than doubling of progression-free survival compared with fulvestrant alone in patients with endocrine-resistant estrogen receptor-positive advanced breast cancer.
Margetuximab Superior to Trastuzumab on PFS in HER2-Positive Metastatic Breast Cancer Carriers of CD16A-F Allele
Margetuximab, a novel Fc-engineered HER2-targeted antibody, improved progression-free survival compared with trastuzumab in patients with pretreated HER2-positive metastatic breast cancer in the open-label phase III SOPHIA clinical trial. 
High TMB Metastatic Breast Cancer Responds to Pembrolizumab Monotherapy
Examination of a cohort of patients with metastatic breast cancer and high mutational burden who were enrolled in the phase II Targeted Agent and Profiling Utilization Registry basket study shows that pembrolizumab monotherapy has antitumor activity in this population of heavily pretreated patients.
Ribociclib Improves Survival by Nearly 30% for Premenopausal Women With Advanced Breast Cancer
Ribociclib plus endocrine therapy demonstrated an estimated overall survival rate of 70.2% at 42 months compared 46.0% for placebo and endocrine therapy in premenopausal women with HR-positive, HER2-negative advanced breast cancer.
COTA, FDA Agree to Collaborate on Breast Cancer Research
COTA, Inc., a leading precision medicine technology company, has signed a 2-year Research Collaboration Agreement with the FDA’s Information Exchange and Data Transformation program.
FDA Grants Lasofoxifene Fast Track Designation for ER+/ESR1-Mutant Metastatic Breast Cancer
The FDA has granted a fast track designation to lasofoxifene for use as a treatment of female patients with estrogen receptor–positive, HER2-negative metastatic breast cancer who harbor ESR1 mutations.
Publication Bottom Border
Border Publication